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Whereas lung transplantation is the only therapeutic option in CF patients with
end-stage pulmonary disease, patients colonized with multiresistant organisms such
as Burkholderia species and especially B. cenocepacia are at risk of postoperative
infections and poor outcomes, and often considered non eligible. In the present
study, we report the clinical outcomes in 19 patients transplanted between 2005 and
2007 and colonized with Burkholderia species (B. cenocepacia: 4; B. multivorans:
8; B. pyrrocinia: 1; B. vietnamiensis: 2; B. gladioli: 1), or Ralstonia mannitolilytica
(3 patients). Perioperative or early septicaemia occurred in 6 patients, caused by
B. cenocepacia (1 patient), B. multivorans (2 patients), B. vietnamiensis (1 patient),
B. gladioli (1 patient) and R. mannitolilytica (1 patient). One late septicaemia (at
month 15) occurred in a B. multivorans infected patient. Eleven of the 19 patients
died, and ﬁve deaths were related to postoperative infectious complications. Eight
of the 19 patients are still alive, 10 to 34 months after transplantation. In summary,
this study shows that B. cenocepacia, but also other members of the B. cepacia
complex, as well as B. gladioli and R. mannitolilytica may be responsible for
post-tranplantation systemic infections, and that the evaluation of patient eligibility
requires further reﬁnement of outcome predictive criteria.
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Objective: To ascertain the in vitro activity of tigecycline (TGC) and other
antibiotics against Burkholderia cepacia complex (Bcc) and other CF-associated
Gram negative bacteria.
Methods: 159 non-duplicate isolates, comprising of B. multivorans (BM) (38
isolates), B. cenocepacia (BC) (23), other Bcc members (12), S. maltophilia (SM)
(49), A. xylosoxidans (AX) (20) and other species (16) were used. MICs of TGC
and 10 other agents were determined using Etest. Synergy testing with TGC in
combination with one of eight other agents was performed using an Etest method.
Results: TGC exhibited good activity against AX and SM, with 85% and 78%
of isolates susceptible. However, only 9% of BC, 3% of BM, and 33% of other
Bcc members were TGC-susceptible, compared to 83% of BC, 92% of BM and
92% of other Bcc members being minocycline-susceptible. Antagonism between
TGC and other agents was rarely encountered, except when used with colistin. The
occurrence of synergy between TGC and others was variable. The most synergistic
combination against Bcc was with ceftazidime, with enhanced activity against 17%
of BC and 24% of BM. Synergy with meropenem was less common with enhanced
activity occurring against 0% of BC and 21% of BM.
Conclusions: These data suggest TGC is a useful option against some difﬁcult-to-
treat Gram-negative pathogens in people with CF, and could be used as an alternative
to an aminoglycoside when combined with a beta-lactam. Clinical studies are needed
to ascertain the correlation between in vitro susceptibility, synergy testing and
patient outcomes.
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Burkholderia gladioli, primarily known as a plant pathogen, is involved in hu-
man infections, especially in patients with cystic ﬁbrosis (CF). In the present
study, the ﬁrst respiratory isolates recovered from 14 CF and 4 non CF French
patients, identiﬁed by use of 16S rDNA analysis, were tested for growth on
B. cepacia selective media, identiﬁcation with commercial systems, antimicrobial
susceptibility, and compared using PFGE.OFPBL and PCA media grew all 18
isolates, and BCSA only 13. API20NE strips did not differentiate B. gladioli from
B. cepacia, whereas Vitek2 GN cards provided identiﬁcation to the species level.
Some misidentiﬁcations occurred with both systems. All isolates were susceptible
to piperacillin, imipenem, aminoglycosides and ciproﬂoxacin. Fifteen PFGE types
were observed among the 18 isolates, but shared types were not identiﬁed within
epidemiologically related patients. Colonization was chronic in 3 of 13 documented
CF patients, and B. gladioli was isolated from post-transplant blood cultures in
1 patient. In non CF patients, B. gladioli was associated with intubation (3 cases) or
bronchiectasis (1 case). In summary, inclusion of B. gladioli in recent commercial
identiﬁcation systems’ databases should improve diagnosis. In CF, this organism
is more frequently involved in transient than in chronic infections, but may be
responsible for post-transplant complications; patient-to-patient transmission has
not been demonstrated to-date. Lastly, B. gladioli appears naturally susceptible to
aminoglycosides and ciproﬂoxacin, though resistant isolates may emerge in the
course of chronic infections.
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Background: The aim of this study was to evaluate chromID P. aeruginosa (PAID)
(bioMe´rieux), a novel chromogenic medium for the isolation and identiﬁcation of
Pseudomonas aeruginosa. This selective medium contains a chromogenic substrate
which when hydrolysed by beta-alanyl aminopeptidase results in the formation of
pigmented colonies.
Methods: Thirty-four sputum samples from 31 CF patients were cultured onto
PAID and on the Pseudomonas cetrimide agar medium (Bio-Rad) routinely used in
the laboratory. The media were incubated aerobically at 37ºC. Growth was noted at
24, 48, 72, 96 and 120 h. All Gram-negative and oxidase-positive colonies culturing
on both media were further identiﬁed by conventional phenotypic methods.
Preliminary results: After 72 h incubation, PAID recovered P. aeruginosa from
13 samples compared with 12 samples for cetrimide agar. All the 13 strains
produced pink or purple colonies on the chromogenic medium after 2 or 3 days of
incubation. While a few other bacterial species could also develop on PAID, none of
them showed the typical pigmentation of P. aeruginosa. Interestingly, more colony
morphotypes were observed on the chromogenic medium compared with cetrimide
agar.
Conclusions: This preliminary study shows that chromID P. aeruginosa is a
sensitive and speciﬁc medium for routine detection of P. aeruginosa in sputa of
CF patients.
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